TrovaGene Inc (NASDAQ:TROV)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.93 and traded as high as $2.54. TrovaGene shares last traded at $2.54, with a volume of 488 shares.
Several research firms recently commented on TROV. Maxim Group set a $8.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Thursday, May 23rd. Noble Financial set a $5.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Friday, May 10th. Zacks Investment Research lowered shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, ValuEngine lowered shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.
The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.76 and a current ratio of 3.76. The company’s fifty day simple moving average is $2.93. The firm has a market capitalization of $12.30 million, a P/E ratio of -0.31 and a beta of 0.90.
TrovaGene (NASDAQ:TROV) last released its earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.05. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%. The company had revenue of $0.16 million for the quarter. On average, sell-side analysts forecast that TrovaGene Inc will post -4.02 EPS for the current fiscal year.
An institutional investor recently raised its position in TrovaGene stock. Vanguard Group Inc. boosted its position in TrovaGene Inc (NASDAQ:TROV) by 508.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 239,029 shares of the medical research company’s stock after acquiring an additional 199,767 shares during the period. Vanguard Group Inc. owned 1.04% of TrovaGene worth $195,000 at the end of the most recent reporting period. 6.04% of the stock is currently owned by hedge funds and other institutional investors.
TrovaGene Company Profile (NASDAQ:TROV)
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.